Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVI-AMG in Outpatients With Asymptomatic or Mild COVID-19
NCT04584697Phase 2Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of plutavimab in coronavirus disease 2019 (COVID-19), sponsored by Sorrento Therapeutics. Planned start Dec 2020; status: withdrawn.
02
Drugs
plutavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04584697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04584697.